<DOC>
	<DOCNO>NCT00231920</DOCNO>
	<brief_summary>This study propose enroll 50 young infant , age 10 22 week . Each fifty infant receive two 0.25mL dos preservative-free Fluzone® , give minimum 28 day apart 42 day apart . Preservative-free Fluzone® administer time routine vaccine . Approximately 2-3mLs blood sample obtain prior first vaccination , approximately 4 week second vaccination 6 month second vaccination measurement immune response . The primary purpose study twofold : 1 . ) To determine safety administer two dos preservative-free Fluzone® young infant 2 . ) To determine capability induce immune response administer two dos preservative-free Fluzone® young infant .</brief_summary>
	<brief_title>Inactivated Influenza Vaccine Infants 10-22 Weeks Age</brief_title>
	<detailed_description>Influenza virus important global cause morbidity mortality . Influenza A B virus cause epidemic disease almost every winter United States average 36,000 death 114,000 hospitalization year 1990s ( superscript 1 ) . Children high rate infection adult great 50 year age high mortality rate ( superscript 2 ) . Influenza , however , associate hospitalization young infant . In survey Tennessee Medicaid database many year , Neuzil et . al report hospitalization rate child less 6 month age much high old child , rate approach 65 year age ( superscript 3 ) . This prospective , phase l , open-label , self-contained , four visit period 7 month , pilot study 50 healthy infant , age 10-22 week , history up-to-date routine immunization , assess safety immunogenicity administer 2 pediatric dos ( minimum 4 week apart ) 0.25 ml trivalent Influenza vaccine ( Fluzone® ) . Each 50 infant receive two 0.25mL dos preservative free Fluzone® , give minimum 28 day apart 42 day apart . Preservative-free Fluzone® administer time routine vaccine . Approximately 2-3 mLs venous blood obtain prior first vaccination , approximately 4 week second vaccination 6 month second vaccination measurement neutralization HAI titer . Infants closely monitor influenza season respiratory symptom , fever , influenza-like illness . They see episode nasal wash collect viral screen include culture influenza virus , respiratory syncytial virus ( RSV ) , adenovirus parainfluenza virus rapid test influenza RSV . Blood collect follow visit , 6 month second dose Fluzone® , use measure post season antibody titer strain influenza A B .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy infant , 1022 week age 2 . Up date routine immunization ( Hepatitis B [ Hep B ] ; diphtheria , tetanus pertussis [ DTaP ] ; pneumococcus [ Prevnar ] ; polio [ IPV ] ; Haemophilus influenzae type B [ Hib ] ) 3 . Free obvious health problem establish medical history clinical examination enter study 4 . Parent/legal guardian willing capable signing write informed consent 5 . Parent/legal guardian expect available entire study 6 . Parent/legal guardian reach telephone . 1 . History hypersensitivity egg egg proteins 2 . Former premature infant ( &lt; 37 week ) 3 . History wheeze use bronchodilator medication 4 . History hospitalization ( exclude birth ) 5 . Significant underlying chronic illness ( i.e . congenital heart defect , bronchopulmonary dysplasia , HIV ) 6 . Immunodeficiency disease use immunosuppressive therapy participant 7 . Any condition clinical judgment investigator might interfere vaccine evaluation 8 . Current enrollment participation clinical trial investigational drug vaccine 9 . Plans participation another clinical trial investigational drug vaccine duration flu study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Weeks</minimum_age>
	<maximum_age>22 Weeks</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Influenza , Vaccine , Infants</keyword>
</DOC>